Q-omics provides the consensus-scored ANAPC1P6 profile across patient tissues and cancer cell-line models. ANAPC1P6 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ANAPC1P6 is differentially expressed in 2, with the highest sampling consensus in KICH. Additionally, ANAPC1P6 RNA expression shows 6,383 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, KICH, and STAD as cancer lineages where ANAPC1P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANAPC1P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANAPC1P6 survival associations across molecular data types. ANAPC1P6 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANAPC1P6 RNA expression–survival associations across cancer types. High ANAPC1P6 expression shows unfavorable associations in KIRC, UVM, KICH, MESO and BLCA, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ANAPC1P6 RNA expression.
This table summarizes ANAPC1P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ANAPC1P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANAPC1P6 shows lower tumor expression in KICH and higher tumor expression in KIRC. The KICH box plot shows higher ANAPC1P6 RNA expression in normal versus tumor tissue (log2 FC = −0.028, t-test p = .014).
This table shows molecular features associated with ANAPC1P6 in patient tissues and cancer cell lines. In patient samples, ANAPC1P6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
